These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 30190353

  • 1. Spindle cell lesion in the bone marrow.
    Guzman S, Kitahara S.
    Blood; 2018 Sep 06; 132(10):1085. PubMed ID: 30190353
    [No Abstract] [Full Text] [Related]

  • 2. Spindle cell morphology in myeloma.
    Mistry J, Murthy V, Giles H, Rudzki Z.
    Br J Haematol; 2021 Jun 06; 193(5):861. PubMed ID: 33655489
    [No Abstract] [Full Text] [Related]

  • 3. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
    Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.
    Blood; 2018 Dec 06; 132(23):2456-2464. PubMed ID: 30249784
    [Abstract] [Full Text] [Related]

  • 4. IgM k multiple myeloma with monoclonal surface immunoglobulin expression.
    Laribi K, Alani M, Lemaire P.
    Int J Hematol; 2018 Jul 06; 108(1):3-4. PubMed ID: 29779080
    [No Abstract] [Full Text] [Related]

  • 5. Primary cutaneous plasmacytoma.
    Matsuda M, Sueda S, Taniguchi T.
    Int J Hematol; 2017 May 06; 105(5):545-546. PubMed ID: 28247190
    [No Abstract] [Full Text] [Related]

  • 6. Multiple myeloma mimicking primary bone tumour.
    Das S, Yanamandra U, Iqbal S, Kapoor R.
    BMJ Case Rep; 2019 Oct 08; 12(10):. PubMed ID: 31594784
    [No Abstract] [Full Text] [Related]

  • 7. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
    Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ.
    Br J Haematol; 2015 Jul 08; 170(1):66-79. PubMed ID: 25824111
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Two diagnoses from bone marrow biopsy: multiple myeloma and Paget's disease of bone.
    Mohamed M.
    BMJ Case Rep; 2016 Feb 24; 2016():. PubMed ID: 26912764
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
    Tuchman SA, Moore JO, DeCastro CD, Li Z, Sellars E, Kang Y, Long G, Gasparetto CG.
    J Geriatr Oncol; 2017 May 24; 8(3):165-169. PubMed ID: 28256432
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
    Uttervall K, Borg Bruchfeld J, Gran C, Wålinder G, Månsson R, Lund J, Gahrton G, Alici E, Nahi H.
    Eur J Haematol; 2019 Sep 24; 103(3):247-254. PubMed ID: 31231833
    [Abstract] [Full Text] [Related]

  • 15. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A, Barbui T, Boccadoro M, Comotti B, Dammacco F, Gallamini A, Marmont F, Neretto G, Petrucci MT, Resegotti L.
    Bone Marrow Transplant; 1989 Jan 24; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
    Jung SH, Choi HJ, Shin MG, Lee SS, Hwang EC, Jung TY, Cho MS, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ.
    Ann Hematol; 2016 Oct 24; 95(10):1645-51. PubMed ID: 27365142
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
    Vandross A.
    Semin Oncol; 2017 Dec 24; 44(6):381-384. PubMed ID: 29935899
    [Abstract] [Full Text] [Related]

  • 20. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
    Sugiura I, Suzuki K, Ri M, Chou T, Takezako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Iida S.
    Int J Hematol; 2020 Jan 24; 111(1):57-64. PubMed ID: 31664647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.